Erleada Cuts Risk of Death by 25% in Localized Castration-resistant Prostate Cancer, Phase 3 Trial Finds

Erleada Cuts Risk of Death by 25% in Localized Castration-resistant Prostate Cancer, Phase 3 Trial Finds
Add-on treatment with Erleada (apalutamide) lowers the risk of death by 25% in men on androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastases, according to updated results of a Phase 3 trial. The research, “Apalutamide (APA) and Overall Survival (OS) in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Updated Results From the Phase 3 SPARTAN Study,” was presented at the 2019 European Society for Medical Oncology (ESMO) Congress and published in the journal Annals of Oncology. The double-blind, placebo-controlled, and multicenter SPARTAN trial (NCT0194620) included 1,207 nmCRPC patients with rapidly rising prostate-specifi
Subscribe or to access all post and page content.